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Immune dysfunctionAutism Spectrum Disorders encompass severe developmental disorders characterized by variable degrees of
impairment in language, communication and social skills, as well as by repetitive and stereotypic patterns of
behaviour. Substantial percentages of autistic patients display peripheral markers of mitochondrial energy
metabolism dysfunction, such as (a) elevated lactate, pyruvate, and alanine levels in blood, urine and/or
cerebrospinal ﬂuid, (b) serum carnitine deﬁciency, and/or (c) enhanced oxidative stress. These biochemical
abnormalities are accompanied by highly heterogeneous clinical presentations, which generally (but by no
means always) encompass neurological and systemic symptoms relatively unusual in idiopathic autistic
disorder. In some patients, these abnormalities have been successfully explained by the presence of speciﬁc
mutations or rearrangements in their mitochondrial or nuclear DNA. However, in the majority of cases,
abnormal energy metabolism cannot be immediately linked to speciﬁc genetic or genomic defects. Recent
evidence from post-mortem studies of autistic brains points toward abnormalities in mitochondrial function
as possible downstream consequences of dysreactive immunity and altered calcium (Ca2+) signalling.D, autism spectrum disorders;
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Autism Spectrum Disorders (ASDs), encompassing Autistic Disor-
der, Asperger's Disorder, and Pervasive Developmental Disorder Not
Otherwise Speciﬁed (PDDNOS), represent a group of severe neuro-
developmental disorders characterized by variable degrees of impair-
ment in language, verbal and non-verbal communication, and social
skills, as well as by repetitive behaviors and an excessive insistence on
sameness, with onset prior to three years of age [1]. Collectively, the
incidence of ASDs has dramatically risen during the last two decades
from 2-5/10,000 to approximately 1-2/1000 children: broader
diagnostic criteria and increased awareness in the medical commu-
nity have certainly contributed to determine this trend, but a real
increase in incidence possibly due to environmental factors cannot be
excluded [2,3]. These disorders are often addressed as discrete clinicalentities, but they should instead be viewed as a continuum, ranging
from minimal autistic traits to severe autism [4].
No neuropsychiatric disorder displays genetic underpinnings as
prominent as those documented by family and twin studies for autism,
with heritability estimates above 90% and sibling recurrence risk as high
as 3–6% for strictly deﬁned autism [3]. However, only in approximately
10% of cases the disease is “syndromic”, i.e. secondary to a known
genetic disorder [3,5],whereas in thevastmajority of patients, theorigin
of “non-syndromic”, “primary” or “idiopathic” autism remains un-
known. Genome-scans unveiled the existence of approximately 15–20
loci contributing to non-syndromic autism, albeit in complex fashion
due to genetic heterogeneity, incomplete penetrance, phenocopies,
gene–gene and gene–environment interactions [3].
The cytoarchitectonic abnormalities present in autistic brains are
most compatiblewith reducedprogrammedcell death and/or increased
cell proliferation, abnormal cell migration, and altered cell differentia-
tion with reduced neuronal size, all pointing toward the ﬁrst/second
trimester of pregnancy as the critical time for deranged neurodevelop-
ment in autism [6,7]. The detection of ﬁne motor symptoms already on
the day of birth or very early on in neonates later diagnosedwith anASD
converges with neuropathological ﬁndings in dating prenatally the
origin of the disease, although behavioral symptoms typically appear at
6–24 months [8–10]. Finally, large subgroups of ASD patients also
display systemic signs and symptoms, including macrosomy [11], non-
speciﬁc enterocolitis [12], immune dysreactivity [12,13] and renal
oligopeptiduria [14]. Autismthus involvesprimarily, but not exclusively,
the central nervous system (CNS) and should be viewed as a multi-
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components.
2. Primary mitochondrial disorders and autism
Interest into possible links between mitochondrial abnormalities
and autism was initially spurred by the deleterious consequences of
mitochondrial disorders on neurodevelopment. Indeed, mitochondri-
al disorders often result in CNS dysfunction, leading to developmental
regression, learning disability, and various behavioural disturbances.
Autism can indeed represent the main clinical presentation of a
mitochondrial disease [15]. However, the clinical manifestations of
mitochondrial disorders, even in the presence of well characterized
mitochondrial DNA (mtDNA) mutations, are extremely heteroge-
neous, ranging from lesions affecting single tissues or organs, such as
the optic nerve in Leber's hereditary optic neuropathy (LHON), or the
cochlea in maternally inherited non-syndromic deafness, to myopa-
thies, encephalomyopathies, cardiopathies, or complex multisystem
syndromes with onset occurring anytime from neonatal to adult life
[16]. Adult patients usually show signs of myopathy, associated with
variable involvement of the CNS (ataxia, hearing loss, seizures,
polyneuropathy, pigmentary retinopathy and,more rarely, movement
disorders). Instead, children most frequently display severe psycho-
motor delay and generalized hypotonia, but symptoms can range
from isolated myopathies, sometimes associated with cardiopathies,
up to fatal multisystem syndromes [17,18]. The occurrence of muscle
‘ragged red ﬁbres’ (RRFs), characterized by a segmental proliferation
and accumulation of abnormal mitochondria under the sarcolemmal
membrane, perhaps represents the best known morphological
hallmark present in many, albeit not all, of these syndromes. Another
common ﬁnding is the presence of muscle ﬁbres that stain negative
using cytochrome oxidase (COX, respiratory complex IV) histochem-
istry. However, these typical ‘mitochondrial’ clues may be absent in
otherwise demonstrated mitochondrial disorders, such as LHON, and
neuropathy ataxia and retinitis pigmentosa (NARP). The same also
occurs in many paediatric cases: lactic acidosis and muscle tissue
histology (even at the level of electronmicroscopy) will be negative in
the majority of affected children, who rarely show “ragged red ﬁbers”
[15]. Finally, molecular investigations still fail to identify the
responsible gene defect in 50% of adults affected by biochemically-
and/or morphologically-deﬁned mitochondrial disease. The percent-
age of undiagnosed cases increases to 80–90% for paediatric disorders
[16].
Geneticmutations inmtDNA have been associatedwithmyopathy,
cardiomyopathy, neuropathy, seizures, optic atrophy, strokes, hearing
loss, diabetes mellitus, and other clinical features [16]. In some cases,
autism can directly stem frommutations in mtDNA, as documented in
the following studies:
1) Pons et al. [19] reported two ASD patients carrying the 3243ANG
mutation, located in the mtDNA tRNALeu(UUR) gene. The same
mutation was also present in the two mothers of two other autistic
children,whose peripheral tissues available for investigation did not
unveil this mutation. The 3243ANG mutation typically causes
mitochondrial encephalopathy with lactic acidosis and stroke-like
episodes (MELAS), but has also been associated with maternally
inherited progressive external ophthalmoplegia, and with develop-
mental delay and seizures [19]. The autistic phenotype in these
mutation carriers appears highly heterogeneous. The behavioral
triad of autistic disorder is often (but not always) associated with
different combinations of neurological signs or symptoms, including
developmental delay, clumsiness, attention deﬁcit, neurologic
deterioration during intercurrent illnesses especially in the presence
of fever, microcephaly or macrocephaly. A ﬁfth child presented with
mitochondrial DNA depletion, which is typically associated with
muscle hypotonia, seizures, myoclonus, and developmental delay.Notably, family history was generally positive for mitochondrial
diseases in the maternal lineage, except in the presence of
mitochondrial depletion.
2) Graf et al. [20] described one autistic patient carrying the 8363GNA
mutation, affecting the mtDNA tRNALys gene. This patient was
characterized by behavioral regression at age 2, extreme hyperac-
tivity, lack of attention, mild ﬁne and gross motor dyspraxia. His
sister was severely affected with partial complex seizures, unsteady
gait, myoclonus, swallowing dysfunction, and moderate cognitive
impairment. Importantly, muscle biopsies unveiled 86% and 61% of
mitochondrial DNA mutated in this girl and in the autistic proband,
respectively, highlighting a probable dosage effect. One of the
patient's two maternal half-sisters suffered from seizures, learning
disabilities, ﬁne tremors and mild motor dyspraxia. Another
maternal half-sister and his mother were neurologically and
psychiatrically healthy.
3) Weissman and Colleagues [21] reviewed the medical records of 25
autistic children with evidence of a deﬁnite or probable (N=21
and 4, respectively) mitochondrial disorder. In addition to the
three core diagnostic features of autism (impaired communica-
tion, social interactions, and repetitive behaviours or restricted
patterns of interest), these patients presented additional signs and
symptoms in various combinations, most commonly including:
(a) excessive fatigability and/or exercise intolerance (N=19, 76%);
(b) gastrointestinal dysfunction (N=16, 64%), in the form of
gastroesophageal reﬂux (N=9, 36%) and/or constipation
(N=8, 32%);
(c) structural or functional cardiovascular abnormalities (N=7,
28%);
(d) facial dysmorphisms (N=6, 24%);
(e) microcephaly (N=4, 16%) or macrocephaly (N=4, 16%);
(f) marked developmental gross motor delays (N=8, 32%); and
(g) growth retardation (N=5, 20%).
Clinical heterogeneity was paralleled by heterogeneity at the
biochemical and genetic levels. Lactate levels were elevated in 19
(76%) patients; defects in complexes I, II, III, and IV, assessed in muscle
and/or ﬁbroblasts, were observed in 64%, 8%, 20% and 4% of patients,
respectively.Magnetic resonance imaging (MRI)was frequently positive
for brain structure abnormalities, detected in 10/21 (47.6%) patients, but
no single abnormality appeared speciﬁcally associated. At the genetic
level, three mutations of probable pathogenetic meaning were found:
(a) 3397ANG in the ND1 subunit of complex I; (b) 4295ANG in mtDNA
tRNAIleu, and (c) 11984 TNC in theND4 subunit of complex I. These three
missense mutations all cause aminoacid changes in highly conserved
regions. Three other mutations (3394 TNC, 1039CNT, 11809 TNC) have
unclear pathogenetic relevance.
In addition to mtDNA mutations, gene dosage abnormalities have
been described by Fillano et al. [22] in ﬁve patients with autism
carrying large deletions in their mtDNA. One recurrent deletion of
7.4 kb was present in three patients, whereas the remaining two
patients unveiled at least three large deletions, including the 7.4 kb
deletion. Approximately 5-15% of the mitochondrial genomes
extracted from blood in four of these ﬁve patients carried these
deletions. This leaves open the question of whether and to what
extent mtDNA may undergo deletions more frequently in blood, as
compared to muscle or to nervous tissue. Three of these patients, in
addition to autism, also display ataxia and/or cardiomyopathy.
Several important conclusions can be drawn from these studies:
I) At the clinical level, autistic patients with an underlying
mitochondrial disease can display highly heterogeneous
clinical pictures. Some of their signs and symptoms are not
unusual in idiopathic autism: for example, macrocephaly and
macrosomy are present in approximately 20% of autistic
patients [11]; gastrointestinal dysmotility is relatively frequent
Table 1
Plasma lactate levels (mM) in autistic subjects.
Abnormal/tested (%) Mean Abnormal (SD) Ref value References
9/34 (26.5%) 1.65 (1.07) 1.4 Filipek et al., 2004 [37]
14/69 (20.3%) 3.5 (1.3) 1.15 Oliveira et al., 2005 [36]
13/30 (43.3%) 2.17 (1.7) b1.9 Laszlò et al., 1994 [35]
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and in ASDs [15], and by no means speciﬁc of ASDs among
neurodevelopmental disorders. However, neurological signs
and symptoms such as oculomotor abnormalities, hearing
deﬁcits, dysarthria, ptosis, hypertonia andmovement disorders
are indeed atypical for autism and were found in 15/25 (60%)
children described by Weissman et al. [21] who also reports
24/25 (96%) of the children displaying at least 1 major clinical
ﬁnding relatively uncommon in idiopathic ASD and 21/25
(84%) patients with an involvement of at least one organ/
system outside the CNS. Regression occurs rather frequently,
especially in the presence of fever [21,23].
II) At the laboratory level, autistic patients with an underlying
mitochondrial disease also display a high degree of heteroge-
neity, but almost all children display abnormalities in at least
one biochemical parameter among several typically assessed to
screen for mitochondrial disorders (i.e., increased blood levels
of lactate, pyruvate, alanine; abnormal urinary levels of organic
acids; increased lactate/pyruvate ratio in ﬁbroblasts).
III) At the morphological level, the incidence of microcephaly and
microsomy is elevated, reaching approximately 20%, likely due
to high incidence of developmental delay. At the neuroimaging
level, neuroanatomical abnormalities are relatively frequent,
although by no means consistent [15,21,23].
IV) At the epidemiological level, these patients display an M:F sex
ratio close to 1:1, whereas the M:F ratio in ASD is skewedmuch
more toward males being affected with a 4:1 probability [24].
Furthermore, an excess of neurological or neurodevelopmental
syndromes of suspect mitochondrial origin is often present in
the maternal lineage.
V) At the genetic level, mtDNA mutations or gene dosage
abnormalities of pathogenetic signiﬁcance are present only in
a small minority of ASD patients with signs and symptoms of
mitochondrial disorders, and collectively represent a rare cause
of illness in unscreened samples of idiopathic autistic children.
Furthermore, no compelling evidence of an association of any
mitochondrial haplogroup to the risk of developing autism has
been found in a large population study [25]. Since mitochon-
drial functioning has been estimated to require approximately
1500 nuclear genes [26] and oxidative phosphorylation
(OXPHOS) involves at least 80 proteins, only 13 encoded by
mtDNA [16], searches for mutations and chromosomal rear-
rangements in nuclear DNA are also warranted. The chromo-
somal rearrangements, or Copy Number Variants (CNVs),
described in autistic patients and possibly involving mitochon-
drial function consist in deletions located in chromosomal
regions 15q11-q13 (cytochrome C oxidase subunit 5A, COX5A),
13q13-q14.1 (mitochondrial ribosomal protein 31, MRPS31),
4q32-q34.68 (electron-transferring-ﬂavoprotein dehydroge-
nase, ETFDH), 2q37.3 (NADH dehydrogenase ubiquinone 1
alpha subcomplex 10, NDUFA10), as recently reviewed by
Smith et al. [27]. Null mutations in other genomic loci known to
be involved in mtDNAmetabolism have not been reported, but
could lead, if present, to mitochondrial depletion [26] of the
kind described by Pons et al. in their ASD patient n.5 (see
above) [19]. However, collectively CNVs are only present in
approximately 7–10% of ASD patients [27]. Considering that
not all of them are autism-speciﬁc (1–2% of controls also carry
CNVs) and that not all of them necessarily affect genes relevant
to mitochondrial function, also the number of cases explained
by CNVs and mutations present in the cell genome can hardly
reach the 20–40% of cases consistently showing elevated
lactate levels. In this majority of ASD patients, who are devoid
of genetic mutations or genomic CNVs directly impacting
mitochondrial function, biochemical signs and clinical symp-
toms of abnormal mitochondrial function are most likelydownstream of pathogenetic processes critically involved in
the origin of ASDs.
3. Mytochondrial dysfunction in idiopathic autism
spectrum disorders
Several studies have described an association between autism
spectrum disorders and mitochondrial dysfunction [22,28,29], and an
impairment of mitochondrial energy metabolism has been proposed
to play a role in autism pathogenesis [30,31]. Mitochondrial dys-
function in the CNS of autistic individuals is supported by neuroima-
ging studies using positron emission tomography (PET) and nuclear
magnetic resonance (NMR) spectroscopy, demonstrating reduced
glucose utilization and diminished ATP levels especially in association
areas of the cerebral cortex [32,33]. At the biochemical level, lactic
acidosis has frequently been found in autism [34]. Three independent
studies [35–37] reported moderate lactic acidosis (see Table 1) and
elevated alanine levels in unselected samples of idiopathic ASD
patients. In a larger cohort [38], a subset of ASD patients with
increased lactate was also found to exhibit the biochemical features of
mitochondrial disease, whose incidence in ASD was estimated at
approximately 6%. Further case-control studies conﬁrmed elevated
plasma lactate in autism [39,40]. Also carnitine deﬁciency is
commonly found in autistic patients [37]. Carnitine is essential for
the utilization of fatty acids by the mitochondria, and carnitine
deﬁciency results in impaired beta oxidation and decreased availabil-
ity of high-energy phosphate compounds. Biomarkers of fatty acid
elongation and desaturation, namely poly-unsaturated long-chain
fatty acids (PUFA) and/or saturated very long chain fatty acids
(VLCFA) containing ethanolamine phospholipids, were signiﬁcantly
elevated in autism, as a consequence of impaired mitochondrial beta
oxidation [31]. Furthermore, in several studies of individuals
presenting with autism increased ammonia has also been described
[37].
Additional evidence pointing toward abnormal mitochondrial
function in autism comes from investigations addressing oxidative
stress. Under normal conditions, a dynamic equilibrium exists between
the production of reactive oxygen species (ROS) such as superoxide
anion, hydroxyl radical, singlet oxygen, and hydrogen peroxide, and the
antioxidant capacity of the cell,which involves bothenzymatic andnon-
enzymatic processes. On one hand, the inner membrane of the
mitochondria contains a large amount of free radical scavengers
including glutathione, vitamin C, and vitamin E, as well as anti-oxidant
enzymes such as superoxide dismutase (SOD). On the other hand,
mitochondria represent the major cellular source of ROS. Excess
production of free radicals or impaired antioxidant mechanisms may
cause oxidative stress: impaired mitochondrial function then leads to
further oxidative stress and a vicious negative cycle can ensue.
Converging evidence suggests that increased oxidative stress may
be present in a sizable subgroup of autistic patients [41–44], where
this harmful cycle is likely to be active and to persist. First, total
glutathione (GSH+GSSG), and free reduced glutathione (GSH) were
signiﬁcantly decreased in plasma of children with autism when
compared to normal children, while the oxidized disulﬁde form of
glutathione (GSSG) was increased [45–47] (see Table 2). Similar
results were observed in lymphoblastoid cells by James at al. [48]. The
glutathione redox ratio (GSH/GSSG) and oxidized glutathione
concentrations are dynamic indicators of cytosolic and mitochondrial
Table 2
Comparison of plasma biomarkers of mitochondrial dysfunction and oxidative stress between autistic children and control children.
ASD/control Mean ASD (SD) Controls mean (SD) Units References
Lactate 15/15 15.3 (3.1) 10.9 (1.9) mg/dL Chugani et al., 1999 [39]
15/15 1.398 (0.819) 0.872 (0.335) mmol/L Al-Mosalem et al., 2009 [40]
GSH 30/30 22.65 (8.1) 31.1 (11) μg/ml Al-Gadani et al., 2009 [43]
28/120 3.1 (0.53) 4.2 (0.72) μmol/L Geier et al., 2009 [46]
80/73 5.1 (1.2) 7.53 (1.7) μmol/L James et al., 2006 [45]
10/10 21.72 (4.3) 26.48 (3.5) (nmol/mg)a James et al., 2009 [48]
GSSG 80/73 0.4 (0.2) 0.24 (0.1) μmol/L James et al., 2006 [45]
10/10 0.356 (0.06) 0.287 (0.07) (nmol/mg)a James et al., 2009 [48]
28/120 0.46 (0.16) 0.35 (0.05) μmol/L Geier et al., 2009 [46]
MDA 11/11 0.4969 (0.025) 0.396 (0.019) nmol/ml Chauhan et al., 2004 [42]
27/26 0.032 (0.0077) 0.015 (0.0033) (mmol/gHb)b Zoroglu et al., 2004 [44]
30/30 15.34 (4.8) 9.92 (4.1) μmol/ml Al-Gadani et al., 2009 [43]
Vitamin E 30/30 0.64 (0.39) 1.86 (0.47) mg/dL Al-Gadani et al., 2009 [43]
Methionine 80/73 20.6 (5.2) 28.0 (6.5) μmol/L James et al., 2006 [45]
SAM:SAH 4.0 (1.7) 5.5 (2.8)
Adenosine 0.28 (0.13) 0.19 (0.13) μmol/L
Homocysteine 5.7 (1.2) 6.0 (1.3) μmol/L
Cystathione 0.24 (0.1) 0.19 (0.1) μmol/L
Cysteine 165 (14) 207 (22) μmol/L
a Lymphoblasts.
b Erythrocytes.
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under physiological conditions, glutathione reductase activity is
sufﬁcient to maintain an elevated reduced/oxidized glutathione
ratio. However, excessive intracellular oxidative stress, exceeding
the capacity of glutathione reductase, will result in oxidized
glutathione export to the plasma in an attempt to regain intracellular
redox homeostasis. Thus, an increase in plasma oxidized glutathione is
a strong indication of intracellular oxidative stress.Moreover, oxidized
glutathione export represents a net loss of glutathione to the cell and
increases the requirement for cysteine, the rate-limiting amino acid for
glutathione synthesis. The decrease in cysteine, methionine, and S-
adenosylmethionine/S-adenosylhomocysteine ratio (i.e., an indicator
ofmethylation capacity), recorded in the plasma of autistic patients by
James et al. [45], paralleled by decreased glutathione levels, and
reduced/oxidized glutathione ratios (Table 2), lends further support to
the existence of an unbalanced redox homeostasis in autism, due to
enhanced oxidative stress and reduced antioxidant capacity. Thirdly,
some ASD children also present an increase in biomarkers of lipid
peroxidation [42,44,49], such as malonyldialdehyde (MDA), an end
product of the peroxidation of polyunsaturated fatty acids and related
esters [36,37]. Furthermore, it has been claimed that α-tocopherol or
vitamin E is the most important lipid-soluble antioxidant, and that it
protects membranes from oxidation by reacting with lipid radicals
produced in the lipid peroxidation chain reaction: a marked decrease
in vitamin E levels has been reported in autistic children compared to
controls [43] (Table 2). Lastly, decreased activities of several
antioxidant enzymes including SOD [50] glutathione peroxidase [50],
catalase [44], and paraoxonase [51,52] have been detected in a
signiﬁcant subgroup of autistic patients.
4. Novel insights into the pathogenetic underpinnings of ASDs
from post-mortem studies of autistic brains
As described above, many ASD patients display biochemical signs
of abnormal mitochondrial function in the absence of genetic
mutations or genomic CNVs directly impacting mitochondrial bio-
chemistry. In order to shed light on the link between mitochondrial
dysfunction and the pathogenetic underpinnings of autism, we have
recently assessed possible roles for the SLC25A12 gene and for its
protein product in autism spectrum disorders [53]. We shall now
brieﬂy summarize our ﬁndings, whichmay serve as a useful paradigm
to disclose possible mechanisms underlying secondary mitochondrial
dysfunction in autism.SLC25A12 is located on human chromosomes 2q24 and encodes for
AGC1, the mitochondrial aspartate/glutamate carrier isoform pre-
dominantly expressed in the brain, heart and skeletal muscle [54,55].
AGC plays a pivotal role in energy metabolism by transporting
glutamate into mitochondria across the inner mitochondrial mem-
brane in exchange for matrix aspartate, a key step in the malate/
aspartate NADH shuttle [54,55]. Importantly, AGC activity is regulated
by intracellular Ca2+ through four “EF-hands” [56] located at its N-
terminus, hanging into the intermembrane space [54,55]. Cytosolic
Ca2+, which is in equilibrium with the mitochondrial intermembrane
space, can rapidly activate AGC transport, thereby increasing the
NADH/NAD ratio in the mitochondrial matrix and consequently
boosting electron ﬂow through the respiratory chain and ATP
generation by OXPHOS [54,55,57]. Through this mechanism, AGC1
plays an essential role in transducting small Ca2+ transients to
neuronal mitochondria [55]. However, an excessive amplitude and/or
duration of Ca2+ spikes leading to AGC activation can contribute to
the formation of ROS and to oxidative stress [58]. Genetic and/or
environmental factors could thus interfere with neuronal ATP produc-
tion and with oxidative stress by affecting the AGC1 carrier, either
directly or throughCa2+homeostasis. Ramoz et al. (2004) raised interest
in this molecule among autism investigators, reporting a signiﬁcant
association between autism and SLC25A12 gene variants marked by the
G allele at two intronic single nucleotide polymorphisms (SNPs), namely
rs2056202 (I3-21ANG) and rs2292813 (I16+70ANG) [59].
In our study, we have assessed AGC function and SLC25A12
genetics, using two parallel approaches: (a) examining AGC transport
rates, AGC1 expression levels and SLC25A12 genomic DNA and cDNA
sequences in post-mortem temporocortical gray matter (Brodmann
area 41/42 or 22) of six pairs of idiopathic ASD patients and sex-, age-,
and post-mortem interval (PMI)-matched controls; (b) performing a
family-based genetic association study using genomic DNA extracted
from 309 simplex and 17 multiplex families with a non-syndromic
autistic proband. The post-mortem study was performed on neocor-
tical tissue from the superior temporal gyrus, because this region has
been convincingly shown to host structural and functional abnormal-
ities in autistic individuals [60]. Biochemical ﬁndings can be brieﬂy
summarized as follows: (a) an approximately three-fold increase in
AGC transport rates was found in tissue homogenates from each of the
six ASD patients compared to their matched controls. This increase
was correlated neither with a clinical history of seizures and EEG
abnormalities, nor with presence/absence or type of pharmacological
treatment prior to death. Instead, excessive transport rates were
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AGC transport rates was found in isolated mitochondria from patients
and controls following removal of the Ca2+-containing post-mito-
chondrial supernatant; (b) when isolated mitochondria from each
control were split into two aliquots, each exposed in parallel either to
his/her own post-mitochondrial supernatant, or to the supernatant of
his/her autistic match, AGC transport rates were activated 3.2- vs 1.7-
fold by the patient and control supernatants, respectively (Pb0.05).
Also this difference was blunted by EGTA; (c) ﬁnally, direct
ﬂuorimetric measurements of Ca2+ levels in the post-mitochondrial
supernatant conﬁrmed signiﬁcantly higher Ca2+ levels in all six
patients, compared to their matched controls; (d) AGC1 expression
(RNA and protein levels) and cytochrome c oxidase activity were both
increased in autistic patients, indicating an activation of mitochon-
drial metabolism; and (e) oxidized mitochondrial proteins were
markedly increased in 5/6 patients vs 1/6 controls [53].
The extent and consistency of these biochemical ﬁndings strikingly
contrasts with the paucity of genetic ﬁndings on the SLC25A12 gene
[53]. Sequencing the genomic DNA and cDNA extracted from the same
brain tissues, unveiled only ﬁve known SNPs, none of them associated
with the biochemical abnormalities described above. In addition, no
evidence of genetic variants associated with ASDs was found in our
genetic sample, although the unaffected brothers and sisters of
autistic patients in our sample tend to inherit more frequently than
expected by chance a “protective” SLC25A12 genetic variant. We can
thus conﬁdently exclude that genetic variants, in the form of either
non-synonymous coding mutations or common functional SNPs,
represent the primary cause of the excessive AGC transport activity,
mitochondrial metabolism and, to a more variable degree, oxidative
stress documented in the autistic brain tissue samples assessed in our
study. Instead, abnormal functioning appears secondary to excessive
Ca2+ levels. Importantly, an excess of AGC1 transport activity due to
overexpression of SLC25A12 has been shown to yield enhanced
neurite growth in vitro [61]. Moreover, AGC1 activity signiﬁcantly
modulates myelination rates through the synthesis of N-acetylaspar-
tate, a critical intermediate in myelin formation [62]. In fact, humans
and animals entirely devoid of AGC1 display profound cerebral
hypomyelination [63,64]. Hence, the abnormal hyperactivation of
AGC1 we recorded in post-mortem tissue, if present in vivo, could
yield neurodevelopmental consequences at the structural level,
perhaps contributing to explain the overgrowth of neocortical brain
regions recorded during the ﬁrst few years of postnatal life in many
autistic children [65,66].
The existence of altered Ca2+ signalling in autism is supported by
several converging lines of research [67]. Timothy syndrome, a
multisystem disorder including autism and mental retardation, is
caused by gain-of-function mutations in the L-type voltage-gated Ca2+
channel Cav1.2 (CACNA1C) [68]. Similarly, gain-of-functionmutations in
the L-type voltage-gated Ca2+ channel Cav1.4 (CACNA1F) cause an
incomplete form of X-linked congenital stationary night blindness
(CSNB2) frequently accompanied by cognitive impairment and either
autism or epilepsy, whereas CSNB2 due to loss-of-function CACNA1F
mutations is not accompanied by these neurodevelopmental compo-
nents [69]. Ingeneral, these gain-of-functionmutationspreventvoltage-
dependent channel inactivation, yielding excessive Ca2+ inﬂux. Also
mutations indirectly boosting cytosolic Ca2+ levels or amplifying
intracellular Ca2+ signalling by hampering Ca2+-activated negative
feedback mechanisms have been found associated with autism [67,70].
Post-mortem studies do not allow to unravel the mechanisms
responsible for enhanced Ca2+ levels in vivo. Nonetheless, two other
recent studies using brain tissue specimens largely overlapping with
thoseassessedbyPalmieri et al. [53], can signiﬁcantly contribute toplace
the chain of events centred around AGC1 into its proper framework:
(a) Garbett et al. [71] performed a genome-wide expression study
on some of the same brain tissue specimens assessed byPalmieri et al. [53]. They found 130 genes showing increased
expression, whereas 22 genes were down-regulated in the
brains of autistics subjects compared to controls. Upregulated
genes fall into 31 gene sets, and as many as 19 of them are
involved in targeting of the immune response to speciﬁc cells
(NKT pathway), inﬂammation (NFKB, IL1R, INFLAM, GSK3,
P38MAPK, IL6, NTHI, and TH1TH2 pathway), cell death (NFKB,
TNFR2, P38MAPK, TID, 41BB, CASPASE, and FAS pathway),
autoimmune diseases (NFKB, TOB1 and FAS pathway), migra-
tion (MCALPAIN pathway) and antigen-speciﬁc immune
response (TOLL, TNFR2, HIVNEF, DC and IL2R pathway).
Altogether these patterns of expression were most consistent
with an inability to attenuate a cytokine activation signal, as
occurs in the late recovery phase of autoimmune brain
disorders. Instead, several downregulated genes were involved
in neuronal differentiation and outgrowth, which is suggestive
of altered neurodevelopment as a consequence of dysreactive
autoimmunity.
(b) Lintas et al. [72] assessed the involvement of the PRKCB1 gene
in autism both at the genetic and post-mortem level. PRKCB1
generates two mRNA isoforms named PRKCB1-1 and PRKCB1-
2, yielding the two PKCβ isoenzymes βΙ and βΙΙ, expressed in
CNS, immune system, digestive tract and kidney. Downregula-
tion of PKCβ either by homologous recombination or by
selective pharmacological inhibition is associated with immu-
nosuppression, reduced oxidative stress, and blunted gene
expression for chemokines such as ICAM-1, MCP-1, and TGFβ
[73–76]. Instead, activation of PKCβ boosts oxidative stress
[77,78]. At the genetic level, Lintas et al. [72] assessed a sample
of 229 simplex and 5 multiplex families with an autistic
proband, detecting a signiﬁcant association between ASD and a
“risk” allele marked by a speciﬁc haplotype located in intron 2.
At the post-mortem level, temporocortical tissue specimens of
ASD patients unveiled a profound decrease in PRKCB1 gene
expression for both isoforms, at the RNA and protein levels.
Importantly, decreased gene expression characterizes patients
carrying the “normal” PRKCB1 allele, whereas patients homo-
zygous for the “risk” conferring allele identiﬁed in our genetic
study display mRNA levels comparable to those of controls.
Whole genome expression analysis [71] unveils a partial
disruption in the coordinated expression of PKCβ-driven
genes, including several cytokines: the positive correlation
generally present in controls, becomes a strong negative
correlation in ASD patients. These results argue against
PRKCB1 driving the ongoing immune activation documented
by Garbett et al. [71] and the enhanced oxidative stress shown
by Palmieri et al. [53] in patient samples. On the contrary, a
compensatory downregulation in PRKCB1 gene expression
occurs in ASD patients, most likely in an attempt to buffer an
inappropriate activation of the immune system. Results from
these two studies are in agreement with previous reports
demonstrating an ongoing immune reaction in a set of post-
mortem brain tissue samples of autistic patients largely non-
overlapping with ours, and in the CSF of autistic children
collected in vivo [79].
Altogether, these studies from ours and other groups, point toward
an abnormal neuroimmune response as a relevant player in elevating
intracellular Ca2+ levels, deranging neurodevelopment, driving
oxidative stress, and ultimately affecting synaptic function and neural
connectivity especially in long-range neuronal pathways physiologi-
cally responsible for integrated information processing (Fig. 1) [80].
Cytokines, such as TNF-α and IL6, and cytokine receptors, like CD38,
are all known to mobilize intracellular calcium stores and/or to
facilitate calcium entry from the extracellular compartment
[71,79,81]. Increased cytoplasmic Ca2+ levels producing mitochondri-
Fig. 1. Pathogenetic model proposed to underlie immune-driven forms of autism
spectrum disorders. Molecules discussed in the present article are highlighted in italics.
Genetic forms of the disease can be due to mutations or CNVs affecting genes critical to
each step of the cascade.
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OXPHOS have been described during the course of HCV infection, a
condition characterized by a persistent activation of the immune
system [82]. Interestingly, an 8-year-old female control who died of a
heart transplant rejection, displayed an EGTA-sensitive AGC activation
reaching levels intermediate between those recorded in autistic
patients and in other controls [53]. This immune-mediated mecha-
nism could thus characterize a large subgroup of ASD patients, while
others could well be explained either by rare genetic mutations, or by
the coexistence in the same individual of several unfavourable
common gene variants. In these genetically-based cases, mutations,
CNVs or polymorphic variants could affect, among others, mtDNA or
nuclear loci directly involved in mitochondrial function, genes
involved in Ca2+ signalling, or genes critical to down-stream synaptic
function (Fig. 1). In this context, it is worth noting that mitochondria
are key players in cellular Ca2+ handling [58,83] and an increase in
intracellular Ca2+, possibly throughNO and/or oxidative stress, would
in turn be able to trigger an immune response similar to the one
observed in autistic brains.[84–87].
5. Conclusions
Autism Spectrum Disorders are often associated with clinical,
biochemical, or neuropathological evidence of altered mitochondrial
function. In some patients, these signs stem from rare mutations in
their mtDNA, or from mutations or chromosomal rearrangements
affecting nuclear loci involved in mitochondrial function and/or
energy metabolism. Autistic behaviors can here be viewed as part of a
broader mitochondrial disease, typically, though not always, display-
ing relatively unusual neurological or systemic signs and symptoms.
At least some biochemical parameters of diagnostic value in
mitochondrial diseases will also be abnormal in these cases. On the
other hand, the majority of autistic patients displays functional
abnormalities in mitochondrial metabolism seemingly secondary to
pathophysiological triggers, such as genetic mutations affecting loci
involved in Ca2+ signalling, or a dysreactive immune system leading
to elevated cytosolic Ca2+ levels. Within this framework, mitochon-
drial function may play a critical role not just in rarely causing the
disease, but also in frequently determining to what extent different
prenatal triggers will derange neurodevelopment and yield abnormalpostnatal behavior. The understanding of mitochondrial roles in
autism progressively achieved in recent years will soon allow
investigators and clinicians to deﬁne whether and to what degree
targeted therapeutic and perhaps even preventive approaches can be
designed on the basis of a strong pathophysiological rationale.
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